SeaStar_SM_LogoCard.png
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
25 sept. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference
05 sept. 2024 08h00 HE | SeaStar Medical Holding Corporation
DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt
04 sept. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage medical device company developing proprietary solutions to reduce...
SeaStar_SM_LogoCard.png
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update
13 août 2024 16h38 HE | SeaStar Medical Holding Corporation
DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
SeaStar_SM_LogoCard.png
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
23 juil. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, July 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its...
SeaStar_SM_LogoCard.png
CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial
16 juil. 2024 08h30 HE | SeaStar Medical Holding Corporation
Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI trial costs DENVER, July 16, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding...
SeaStar_SM_LogoCard.png
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner
12 juil. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, July 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports the initial commercial sale of QUELIMMUNE™-Pediatric to its U.S. license and...
SeaStar_SM_LogoCard.png
SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 juil. 2024 16h05 HE | SeaStar Medical Holding Corporation
DENVER, July 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that it has closed its previously announced registered offering for the...
SeaStar_SM_LogoCard.png
SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10 juil. 2024 09h00 HE | SeaStar Medical Holding Corporation
DENVER, July 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), today announced it has entered into a definitive agreement for the issuance and sale of...
SeaStar_SM_LogoCard.png
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device
03 juil. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, July 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...